+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

CISCA (cisplatin vs. carboplatin) meta-analysis: An individual patient data meta-analysis comparing cisplatin versus carboplatin-based chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC)



CISCA (cisplatin vs. carboplatin) meta-analysis: An individual patient data meta-analysis comparing cisplatin versus carboplatin-based chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC)



Journal of Clinical Oncology 24(18_Suppl): 7011-7011



NlmCategory="UNASSIGNED">7011 Background: The issue of the equivalence between carboplatin and cisplatin in the treatment of advanced NSCLC is still controversial. To answer this question, we conducted an individual patient (pt) data meta-analysis of randomized trials comparing cisplatin- and carboplatin-based chemotherapy (CT) in first-line treatment of advanced NSCLC. A literature search was performed to identify randomized trials investigating the substitution of carboplatin for cisplatin, combined with the same agent/s, in the first-line CT of advanced NSCLC. The primary end-point was overall survival (OS) and the secondary end-points were response rate (RR) and toxicity. For each end-point the analysis was based on a fixed-effects model. For the study of the effect on OS, Cox proportional hazards model was used. The probability to have an objective response or an adverse event was studied using a logistic regression model. Nine trials were identified and the relative databases obtained. In total, 2,968 pts were randomized to receive CT with cisplatin (1,489) or with carboplatin (1,479), respectively. The RR was 30% and 24% for cisplatin- and carboplatin-based CT, respectively, with an OR of 1.37 (95% C.I.: 1.16-1.62; p < 0.001). Concerning the OS, carboplatin was associated with a relative risk of death 7% higher compared with cisplatin, even if this difference was not statistically significant (HR = 1.07; 95% C.I.: 0.99-1.15; p = 0.101). Patients on cisplatin-based CT had more nausea-vomiting and nephro-toxicity while thrombocytopenia was more frequent during carboplatin-based CT. Subgroup analyses revealed that cisplatin-based CT led to statistically significant advantage in survival in the subgroups of pts with non-squamous tumours and in those treated with third generation CT. CISCA is the first individual pt data meta-analysis on this subject. We found that cisplatin-based is superior to carboplatin-based CT in terms of RR; however, the increased RR does not translate into an OS benefit. Nevertheless, selected pts with advanced NSCLC may obtain slightly more benefit from cisplatin-based third generation CT. No significant financial relationships to disclose.

(PDF emailed within 1 workday: $29.90)

Accession: 057336869

Download citation: RISBibTeXText

PMID: 27953227


Related references

Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. Journal of the National Cancer Institute 99(11): 847-857, 2007

Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced NonSmall-Cell Lung Cancer: An Individual Patient Data Meta-analysis. Yearbook of Oncology 2008: 165-167, 2008

Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. Journal of Clinical Oncology 30(14): 1692-1698, 2012

Meta-analysis comparing carboplatin and cisplatin-based chemotherapy in advanced non-small cell lung cancer. Journal of Clinical Oncology 23(16_Suppl): 7218-7218, 2016

A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer 57(3): 348-358, 2007

O-236 Meta-analysis of randomized trials evaluating cisplatin or carboplatin-based concomitant chemoradiation versus radiotherapy alone in locally advanced non-small cell lung cancer (NSCLC). Lung Cancer 41: S69-S70, 2003

Meta-analysis of Randomized Clinical Trials Comparing Cisplatin to Carboplatin in Patients With Advanced Non-Small-Cell Lung Cancer. Yearbook of Oncology 2006: 199-201, 2006

Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology 22(19): 3852-3859, 2004

Paclitaxel-etoposide-carboplatin/cisplatin versus etoposide-carboplatin/cisplatin as first-line treatment for combined small-cell lung cancer: a retrospective analysis of 62 cases. Cancer Biology and Medicine 12(2): 117-125, 2015

Cost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in Italy. Lung Cancer 48(3): 379-387, 2005

First-line chemotherapy treatment of advanced non-small-cell lung cancer: does cisplatin versus carboplatin make a difference?. Journal of Thoracic Oncology 9(11): E82, 2015

A meta-analysis comparing cisplatin-based to carboplatin-based chemotherapy in moderate to advanced squamous cell carcinoma of head and neck (SCCHN). Oncotarget 7(6): 7110-7119, 2016

A meta-analysis of randomized controlled trials comparing early and late concurrent thoracic radiotherapy with etoposide and cisplatin/carboplatin chemotherapy for limited-disease small-cell lung cancer. Molecular and Clinical Oncology 2(5): 805-810, 2014

Cisplatin and carboplatin-based chemotherapy in the first-line treatment of non-small cell lung cancer: Analysis from the European FRAME study. Lung Cancer 92: 35-40, 2016

Single agent vs combination chemotherapy (CT) as second-line treatment of advanced non-small-cell lung cancer (NSCLC): A meta-analysis of individual data of five randomized trials. Journal of Clinical Oncology 26(15_Suppl): 8052-8052, 2016